Quantbot Technologies LP Invests $1.25 Million in Inari Medical, Inc. (NASDAQ:NARI)

Quantbot Technologies LP bought a new position in Inari Medical, Inc. (NASDAQ:NARI - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm bought 30,273 shares of the company's stock, valued at approximately $1,248,000. Quantbot Technologies LP owned about 0.05% of Inari Medical as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. GAMMA Investing LLC raised its position in shares of Inari Medical by 164.7% during the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company's stock valued at $34,000 after buying an additional 438 shares during the period. Nisa Investment Advisors LLC raised its position in Inari Medical by 83.5% in the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company's stock valued at $46,000 after purchasing an additional 435 shares during the period. KBC Group NV lifted its stake in shares of Inari Medical by 39.0% in the 3rd quarter. KBC Group NV now owns 1,774 shares of the company's stock valued at $73,000 after purchasing an additional 498 shares during the last quarter. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Inari Medical by 39.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company's stock worth $89,000 after purchasing an additional 522 shares during the period. Finally, Covestor Ltd grew its holdings in shares of Inari Medical by 63.5% during the 3rd quarter. Covestor Ltd now owns 2,384 shares of the company's stock worth $99,000 after purchasing an additional 926 shares during the period. Hedge funds and other institutional investors own 90.98% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on NARI shares. Robert W. Baird upped their target price on shares of Inari Medical from $66.00 to $67.00 and gave the company an "outperform" rating in a research report on Tuesday, October 29th. Truist Financial upped their price objective on shares of Inari Medical from $46.00 to $50.00 and gave the stock a "hold" rating in a report on Tuesday, October 29th. Stifel Nicolaus began coverage on shares of Inari Medical in a report on Tuesday, September 17th. They issued a "hold" rating and a $50.00 target price for the company. Piper Sandler upped their price target on Inari Medical from $50.00 to $52.00 and gave the stock a "neutral" rating in a research note on Tuesday, October 29th. Finally, Leerink Partners initiated coverage on Inari Medical in a research note on Tuesday, September 3rd. They issued a "market perform" rating and a $47.00 price objective for the company. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, Inari Medical presently has a consensus rating of "Hold" and a consensus price target of $58.89.

Insiders Place Their Bets

In other news, CEO Andrew Hykes sold 3,000 shares of the business's stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $50.00, for a total transaction of $150,000.00. Following the completion of the transaction, the chief executive officer now directly owns 445,310 shares of the company's stock, valued at approximately $22,265,500. The trade was a 0.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director William Hoffman sold 40,000 shares of the company's stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $45.02, for a total transaction of $1,800,800.00. Following the sale, the director now owns 601,233 shares in the company, valued at $27,067,509.66. The trade was a 6.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 186,000 shares of company stock worth $8,990,990 in the last quarter. 10.60% of the stock is owned by company insiders.

Inari Medical Stock Performance

Shares of Inari Medical stock traded up $0.89 during trading hours on Friday, reaching $51.92. 287,786 shares of the company were exchanged, compared to its average volume of 711,764. The firm has a market cap of $3.04 billion, a PE ratio of -38.46 and a beta of 0.96. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $67.13. The stock's fifty day moving average is $46.31 and its 200 day moving average is $47.54.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.